PT  - JOURNAL ARTICLE
AU  - Sermet-Gaudelus, Isabelle
AU  - Temmam, Sarah
AU  - Huon, Christèle
AU  - Behillil, Sylvie
AU  - Gajdos, Vincent
AU  - Bigot, Thomas
AU  - Lurier, Thibaut
AU  - Chrétien, Delphine
AU  - Backovic, Marija
AU  - Moisan-Delaunay, Agnès
AU  - Donati, Flora
AU  - Albert, Mélanie
AU  - Foucaud, Elsa
AU  - Mesplées, Bettina
AU  - Benoist, Grégoire
AU  - Faye, Albert
AU  - Duval-Arnould, Marc
AU  - Cretolle, Célia
AU  - Charbit, Marina
AU  - Aubart, Mélodie
AU  - Auriau, Johanne
AU  - Lorrot, Mathie
AU  - Kariyawasam, Dulanjalee
AU  - Fertitta, Laura
AU  - Orliaguet, Gilles
AU  - Pigneur, Bénédicte
AU  - Bader-Meunier, Brigitte
AU  - Briand, Coralie
AU  - Enouf, Vincent
AU  - Toubiana, Julie
AU  - Guilleminot, Tiffany
AU  - van der Werf, Sylvie
AU  - Leruez-Ville, Marianne
AU  - Eloit, Marc
TI  - Prior infection by seasonal coronaviruses does not prevent SARS-CoV-2 infection and associated Multisystem Inflammatory Syndrome in children
AID  - 10.1101/2020.06.29.20142596
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.29.20142596
4099  - http://medrxiv.org/content/early/2020/06/30/2020.06.29.20142596.short
4100  - http://medrxiv.org/content/early/2020/06/30/2020.06.29.20142596.full
AB  - Background Children have a lower rate of COVID-19, potentially related to cross-protective immunity conferred by seasonal coronaviruses (HCoVs). We tested if prior infections with seasonal coronaviruses impacted SARS-CoV-2 infections and related Multisystem Inflammatory Syndrome (MIS).Methods This cross-sectional observational study in Paris hospitals enrolled 739 pauci or asymptomatic children (HOS group) plus 36 children with suspected MIS (MIS group). Prevalence, antigen specificity and neutralizing capability of SARS-CoV-2 antibodies were tested. Antibody frequency and titres against Nucleocapsid (N) and Spike (S) of the four seasonal coronaviruses (NL63, HKU1, 229E, OC43) were measured in a subset of seropositive patients (54 SARS-CoV-2 (HOS-P subgroup) and 15 MIS (MIS-P subgroup)), and in 118 matched SARS-CoV-2 seronegative patients (CTL subgroup).Findings SARS-CoV-2 mean prevalence rate in HOSP children was 11.7% from April 1 to June 1. Neutralizing antibodies were found in 55·6% of seropositive children, and their relative frequency increased with time (up to 100 % by mid-May). A majority of MIS children (25/36) were SARS-CoV-2 seropositive, of which all tested (n=15) had neutralizing antibodies. On average, seropositive MIS children had higher N and S1 SARS-CoV-2 titres as compared to HOS children. Patients from HOS-P, MIS-P, and CTL subgroups had a similar prevalence of antibodies against the four seasonal HCoVs (66·9 −100%). The level of anti-SARS-CoV-2 antibodies was not significantly different in children who had prior seasonal coronavirus infection.Interpretation Prior infection with HCoVs does not prevent SARS-CoV-2 infection and related MIS in children. Children develop neutralizing antibodies after SARS-CoV-2 infection.Evidence before this study Children seem to be less likely affected by SARS-CoV-2 infection and clinical course of COVID-19 is less severe than in adults. As those asymptomatic or mildly symptomatic children are underdiagnosed and their viral loads are comparable to those of adults, they may act as an asymptomatic reservoir for the spread of the virus. One explanation of the difference between the adult and the pediatric infectious profile might be that infection with seasonal human coronaviruses, which is very frequent from a very young age, could lead to cross protective immunity. We searched in PubMed, MedRxiv and BioRxiv for publications from inception to June 15, 2020, using the terms “COVID-19, SARS-CoV-2, children, serology, Kawasaki, Corona Virus”.Added value of this study SARS-CoV-2 mean prevalence rate was 11.7% from April 1 to June 1 and neutralizing antibodies were found in 55% of the tested seropositive children. Among patients with a Multisystem Inflammatory Syndrome, Kawasaki-like disease, 70% were SARS-CoV-2 seropositive and had neutralizing antibodies. COVID-19 and MIS attack rates, and anti-SARS-CoV-2 antibodies titres were not significantly impacted by prior seasonal coronavirus infection.Implications of all the available evidence Prior infection by seasonal coronaviruses does not prevent SARS-CoV-2 infection and associated Multisystem Inflammatory Syndrome in children As antibodies against seasonal coronaviruses are very frequent and as these viruses circulate efficiently in human populations every winter, our results question to what extent the concept of herd immunity based on circulating antibodies can be applied to seasonal coronaviruses and possibly SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe local Ethics (CERAPHP Paris V) approved this study (IRB registration: #00011928)Funding Statement:.ME lab is funded by Institut Pasteur, Labex IBEID (ANR-10-LABX-62-IBEID), Reacting, EU grant Recover, ANR Ohticks. SVDW lab is funded by Institut Pasteur, CNRS, Universite de Paris, Sante publique France, Labex IBEID (ANR-10-LABX-62-IBEID), REACTing (Research & Action Emerging Infectious Diseases), EU Grant 101003589 RECoVER.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The local Ethics (CERAPHP Paris V) approved this study (IRB registration: #00011928).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data of the study will be available on request